On September 2, 2026 Treeline Biosciences, Inc. ("Treeline") reported a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-121, Treeline’s BCL6 degrader, in combination with Roche’s CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in separate combination cohorts for patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Treeline will sponsor and conduct the Phase 1 dose escalation and expansion study, and Roche will supply glofitamab and mosunetuzumab for specific expansion cohorts. Treeline expects to initiate combination dosing for these expansion cohorts in the fourth quarter of 2026.

"CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche," said Josh Bilenker, M.D., co-founder and Chief Executive Officer of Treeline. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumor activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T- and B-cells."

Preclinical Data Support Combination Strategy

TLN-121 has demonstrated single-agent activity in an ongoing Phase 1 clinical trial, including complete responses, in late-line DLBCL, follicular lymphoma (FL), and T follicular helper peripheral T-cell lymphoma (TFH PTCL).

BCL6 is a transcriptional repressor that helps B-cell lymphomas evade immune attack by silencing genes important for effective T-cell interactions. In DLBCL cell lines, TLN-121 restored expression of T-cell-recruiting cytokines and immune synapse genes. Treeline investigated the combination of TLN-121 and T-cell immunotherapies in DLBCL mouse xenograft models that responded suboptimally to either component as a single agent. In an aggressive DLBCL model supplemented with human T-cells, combining TLN-121 with a CD20xCD3 bispecific antibody produced complete regressions in four of six mice, compared with zero of six for TLN-121 alone and one of five for the antibody alone. In an aggressive DLBCL xenograft model, combining TLN-121 with CD19 CAR-T cells shrank tumors in four of six mice and completely regressed tumors in two of six, compared with no tumor shrinkage or regression in any mice for TLN-121 or the CD19 CAR-T alone.

(Press release, Treeline Biosciences, SEP 2, 2026, View Source [SID1234670557])

On September 2, 2026 Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, reported a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset.

Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network.

Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities support human-led analysis and self-driven campaigns for hypothesis generation, testing and prioritization.

"This agreement between Owkin and Boehringer Ingelheim shows how cutting-edge AI has the potential to enable data-driven pharmaceutical research," said Thomas Clozel, CEO and co-founder of Owkin. "We believe the next decade of drug development will be defined by access to deep multimodal patient data and to AI Scientists – like K Pro – capable of reasoning over that data."

(Press release, Owkin, SEP 2, 2026, View Source [SID1234670556])

On September 2, 2026 Typewriter Therapeutics, Inc., a biotech company developing safe, durable and re-dosable genetic medicines with curative impact for patients with cancer, autoimmune diseases, and severe genetic diseases, reported the company emerged from stealth with $56 million in Series A financing led by AN Venture Partners and RA Capital Management with participation from ANRI, Gemseki, and SBI US Gateway Fund. In addition, Typewriter announced the appointments of Matthew Stanton, PhD, as Chief Executive Officer, Leanne Peiser, DPhil, as Chief Scientific Officer, and Mikael Dolsten, MD, PhD, as a member of the company’s board of directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Typewriter’s Target-Primed Reverse Transcription (TPRT) technology platform is built on the R2 retrotransposon, a natural gene-insertion system discovered by the company’s academic co-founders. Typewriter’s two-part, all-RNA therapy comprises a payload mRNA to make the R2 protein and a second RNA containing the therapeutic gene flanked by sequences to recruit the R2 protein. Inside the cell, the two assemble into an active complex that inserts the gene into the specific target site by TPRT. The R2 machinery then degrades along with the mRNA, leaving only the inserted gene at its intended location.

Typewriter’s initial focus will be on two high-value indications with life-changing potential to patients: in vivo CAR T and genetic liver diseases. The company’s first NHP studies are planned for late 2026.

"By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines that are accessible to many more patients than current cumbersome and complex CAR T approaches," said Matthew Stanton, PhD, Chief Executive Officer and Board Director of Typewriter Therapeutics. "This financing enables us to build on the proof-of-concept we have established in humanized mouse models and establish our first in vivo CAR T development candidate."

Prior to Typewriter, Matthew Stanton was a Venture Partner at Raven, RA Capital’s healthcare incubator. Before Raven, he spent seven years at Generation Bio, first as Chief Technology Officer and for the past five years as Chief Scientific Officer. Prior to Generation, he was Vice President and Head of Chemistry at Moderna Therapeutics, where his team identified proprietary lipid nanoparticles for vaccine development and helped to bring the first mRNA vaccines into clinical development.

Newly appointed CSO Leanne Peiser brings to Typewriter more than 20 years of R&D leadership across biotech and pharma, with deep expertise in immunology, immunotherapy, and cellular therapy, including autologous, allogeneic, and in vivo CAR T for oncology and autoimmune diseases. Most recently, as Executive Director of Translational Research, Cellular Therapy at Bristol Myers Squibb (BMS), she served as a senior scientific lead for their CAR T portfolio across multiple indications.

"The mRNA vaccines proved to the world that RNA delivered by a lipid nanoparticle can become a medicine at global scale. Typewriter takes that breakthrough a decisive step further –using only RNA not to express a transient protein, but to write a durable therapeutic gene into a precise, safe location in the genome, without a virus," said Mikael Dolsten, MD, PhD, independent board director at Typewriter Therapeutics and former Chief Scientific Officer and President of Worldwide Research & Development at Pfizer. "I am especially excited by what this means for in vivo CAR T. Engineering a patient’s own T cells in vivo with an LNP-delivered RNA medicine could combine simpler administration with durable CAR expression and the ability to re-dose, potentially making cell therapy safer and accessible to far more patients than today’s complex manufacturing allows. It is a privilege to join the board and help bring this platform to patients with cancer, autoimmune, and genetic diseases."

Typewriter is led by an experienced management team, including:

Matthew Stanton, PhD, Chief Executive Officer
Leanne Peiser, DPhil, Chief Scientific Officer
Jun Zhou, PhD, Founder and Vice President, Discovery and Global Operations
Ari Friedland, PhD, Vice President, Research
Mayu Yoshikawa, PhD, President, Typewriter Japan
In addition to Matthew Stanton and Mikael Dolsten, Typewriter’s board of directors includes board chair Ken Horne, Managing Partner, AN Venture Partners and Laura Tadvalkar, PhD, Managing Director at RA Capital.

Typewriter also announced that Stanley R. Riddell, MD, has joined as a member of its Scientific Advisory Board. Dr. Riddell is a member of the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center and Professor of Medicine at the University of Washington. He was the principal investigator on the first human trial of adoptively transferred therapeutic T cells, and his laboratory’s CAR T work was licensed to Juno Therapeutics, which he co-founded and which is now part of Bristol Myers Squibb.

(Press release, Typewriter Therapeutics, SEP 2, 2026, View Source [SID1234670554])

On September 2, 2026 Amgen (NASDAQ: AMGN) reported it will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Thomas Dittrich, executive vice president and chief financial officer at Amgen, Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

(Press release, Amgen, SEP 2, 2026, View Source [SID1234670555])

On September 2, 2026 NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, reported that it has received regulatory clearance from China’s National Medical Products Administration (NMPA) to initiate a pivotal Phase III clinical study of 177Lu-NYM032 in China. 177Lu-NYM032 is a novel investigational PSMA-targeted, small-molecule therapeutic radiopharmaceutical for radioligand therapy (RLT) independently developed in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Led by the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, a randomized, open-label, multicenter Phase III study is being conducted at multiple sites across China to evaluate the efficacy and safety of 177Lu-NYM032 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

177Lu-NYM032 has demonstrated promising anti-tumor activities and a favorable safety profile in its Phase I/II clinical study, with the data to be disclosed in a Top-Rated Oral Presentation (TROP) at the 2026 Annual Congress of the European Association of Nuclear Medicine (EANM 26). Previously, the corresponding diagnostic radiopharmaceutical pair, 68Ga-NYM032, was dosed in the first patient in a Phase III clinical trial, marking a key milestone in the advancement of the company’s integrated prostate cancer theranostic pipeline. The 68Ga/177Lu-NYM032 theranostic pair has also received U.S. FDA Investigational New Drug (IND) clearance.

The pair of diagnostic and therapeutic agents of NYM032 are derived from the same precursor structure, enabling a fully integrated theranostic approach and offering the potential to provide patients with prostate cancer in China with a more precise and coordinated diagnosis and treatment option.

Prostate cancer is the fifth leading cause of cancer death among men worldwide. In 2022, more than 134,000 patients in China were newly diagnosed with prostate cancer, and approximately 47,500 deaths were reported. A substantial proportion of the patients will eventually progress to have metastatic castration-resistant prostate cancer (mCRPC), an aggressive late-stage form of the disease. At that stage, many patients face limited treatment options after exhausting standard-of-care therapies, thus underscoring the substantial unmet medical need for novel targeted radiopharmaceuticals in China.

(Press release, Norroy Bioscience, SEP 2, 2026, View Source [SID1234670553])